European urology最新文献

筛选
英文 中文
Platinum Hall of Fame 白金名人堂
IF 25.3 1区 医学
European urology Pub Date : 2025-02-17 DOI: 10.1016/j.eururo.2025.01.017
{"title":"Platinum Hall of Fame","authors":"","doi":"10.1016/j.eururo.2025.01.017","DOIUrl":"10.1016/j.eururo.2025.01.017","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 3","pages":"Pages e41-e51"},"PeriodicalIF":25.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congress Calendar 国会的日历
IF 25.3 1区 医学
European urology Pub Date : 2025-02-17 DOI: 10.1016/j.eururo.2025.01.018
{"title":"Congress Calendar","authors":"","doi":"10.1016/j.eururo.2025.01.018","DOIUrl":"10.1016/j.eururo.2025.01.018","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 3","pages":"Pages e56-e57"},"PeriodicalIF":25.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025;87:526–533 回复:Guillaume Ploussard, Patrick colby, Thierry Chevallier等。全腺体或次全高强度聚焦超声与根治性前列腺切除术:前瞻性、非劣效性、非随机的HIFI试验。Urol欧元。在出版社。https://doi.org/10.1016/j.eururo.2024.11.006
IF 25.3 1区 医学
European urology Pub Date : 2025-02-15 DOI: 10.1016/j.eururo.2025.01.023
Francesco Montorsi, Giorgio Gandaglia, Armando Stabile
{"title":"Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025;87:526–533","authors":"Francesco Montorsi, Giorgio Gandaglia, Armando Stabile","doi":"10.1016/j.eururo.2025.01.023","DOIUrl":"10.1016/j.eururo.2025.01.023","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 5","pages":"Page e95"},"PeriodicalIF":25.3,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143417274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Marie-Pier St-Laurent, Bernard Bochner, James Catto, et al. Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.026 Re: Marie-Pier St-Laurent, Bernard Bochner, James Catto等人。泌尿生殖系统恶性肿瘤患者预期寿命增加:治疗负担对疾病管理和生活质量的影响Urol欧元。在出版社。https://doi.org/10.1016/j.eururo.2024.11.026
IF 23.4 1区 医学
European urology Pub Date : 2025-02-15 DOI: 10.1016/j.eururo.2025.01.024
Chang-kun Mao, , Jun-ting Li
{"title":"Re: Marie-Pier St-Laurent, Bernard Bochner, James Catto, et al. Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.026","authors":"Chang-kun Mao, , Jun-ting Li","doi":"10.1016/j.eururo.2025.01.024","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.01.024","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"11 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143418455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer 局部晚期和转移性激素敏感前列腺癌的联合治疗
IF 25.3 1区 医学
European urology Pub Date : 2025-02-12 DOI: 10.1016/j.eururo.2025.01.010
Arun A. Azad , Louise Kostos , Neeraj Agarwal , Gerhardt Attard , Ian D. Davis , Tanya Dorff , Silke Gillessen , Chris Parker , Matthew R. Smith , Christopher J. Sweeney , Bertrand Tombal , Karim Fizazi
{"title":"Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer","authors":"Arun A. Azad ,&nbsp;Louise Kostos ,&nbsp;Neeraj Agarwal ,&nbsp;Gerhardt Attard ,&nbsp;Ian D. Davis ,&nbsp;Tanya Dorff ,&nbsp;Silke Gillessen ,&nbsp;Chris Parker ,&nbsp;Matthew R. Smith ,&nbsp;Christopher J. Sweeney ,&nbsp;Bertrand Tombal ,&nbsp;Karim Fizazi","doi":"10.1016/j.eururo.2025.01.010","DOIUrl":"10.1016/j.eururo.2025.01.010","url":null,"abstract":"<div><h3>Background and objective</h3><div>The treatment landscape for advanced prostate cancer has evolved significantly over the past decade. The introduction of docetaxel, androgen receptor pathway inhibitors (ARPIs), poly(ADP-ribose) polymerase inhibitors, and targeted radionuclides has redefined the treatment paradigm, with a focus now on early treatment intensification through combination therapies. This narrative collaborative review summarises the current evidence of combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer (mHSPC).</div></div><div><h3>Methods</h3><div>We conducted a literature search up to November 2024. Search terms included “metastatic hormone-sensitive prostate cancer”, “metastatic castration-sensitive prostate cancer”, “locally advanced prostate cancer”, “combination”, “intensification”, and “de-escalation”. Articles were selected by the authors based on their scientific merit, clinical impact, and relevance to provide a summary of the evidence surrounding combination therapy in locally advanced prostate cancer and mHSPC.</div></div><div><h3>Key findings and limitations</h3><div>A doublet approach with an androgen deprivation therapy (ADT) backbone and an ARPI is now considered the standard treatment for mHSPC, with a triplet regimen incorporating docetaxel considered in select subgroups. Similar efforts to improve survival in the high-risk localised and locally advanced disease setting have led to several trials evaluating the benefit of combination therapy in addition to standard-of-care surgery or radiotherapy with ADT. Continued improvements in survival have turned the focus to optimising patient selection for treatment intensification and, in some cases, de-escalation, with the goal of reducing unnecessary overtreatment and minimising harm from long-term treatment toxicity. This is particularly important with the integration of prostate-specific membrane antigen positron emission tomography, which has led to the earlier detection of metastatic disease.</div></div><div><h3>Conclusions and clinical implications</h3><div>In select subgroups, early treatment intensification with combination therapy leads to improved survival, though it can be associated with long-term toxicity.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 4","pages":"Pages 455-467"},"PeriodicalIF":25.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer 高危前列腺癌强化新辅助治疗后残留癌负担的长期结局和预后影响
IF 23.4 1区 医学
European urology Pub Date : 2025-02-07 DOI: 10.1016/j.eururo.2025.01.015
Praful Ravi, Lucia Kwak, Andres M. Acosta, Saahil Rastogi, Wanling Xie, Aya Abdelnaser, David J. Einstein, Peter Chang, Andrew A. Wagner, Rana R. McKay, Adam S. Kibel, Mary-Ellen Taplin
{"title":"Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer","authors":"Praful Ravi, Lucia Kwak, Andres M. Acosta, Saahil Rastogi, Wanling Xie, Aya Abdelnaser, David J. Einstein, Peter Chang, Andrew A. Wagner, Rana R. McKay, Adam S. Kibel, Mary-Ellen Taplin","doi":"10.1016/j.eururo.2025.01.015","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.01.015","url":null,"abstract":"<h3>Background and objective</h3>Long-term outcomes and the prognostic impact of the extent of residual disease after neoadjuvant therapy (NAT) with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) before radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC) are not known.<h3>Methods</h3>We analyzed data for patients treated in five trials evaluating 6 mo of ARPI NAT for HRLPC at our institution between 2006 and 2018. Residual cancer burden (RCB) was quantitated as the calculated tumor volume adjusted for cellularity in the primary tumor. The primary outcome was metastasis-free survival (MFS) according to conventional imaging. We explored RCB categories using the Contal-O’Quigley method to distinguish high- and low-risk groups for MFS.<h3>Key findings and limitations</h3>Among 218 eligible patients, median prostate-specific antigen at diagnosis was 8 ng/ml, 42 (20%) had cT3–4 disease, and 154 (71%) had a biopsy Gleason score of 8–10. At RP, 24 (11%) had a pathologic complete response and median RCB was 0.05 cm<sup>3</sup> (interquartile range 0.00–0.32). By median follow-up of 5 yr, 45 patients had developed metastases and 11 died; the 5-yr MFS rate was 83% (95% confidence interval [CI] 77–88%). On multivariable analysis, higher RCB was associated with poorer MFS (hazard ratio 1.21, 95% CI 1.01–1.47). The 5-yr MFS rates were 100%, 90% (95% CI 72–97%), 82% (95% CI 73–88%), and 63% (95% CI 40–79%) for patients with RCB-0 (a pathologic complete response or no residual disease), RCB-1 (&lt;0.003 cm<sup>3</sup>), RCB-2 (0.003–0.672 cm<sup>3</sup>), and RCB-3 (≥0.672 cm<sup>3</sup>), respectively. The key limitation is lack of a validation cohort.<h3>Conclusions and clinical implications</h3>The 5-yr MFS rate for patients treated with ARPI NAT before RP for HRLPC was 83%. The depth of pathologic response, evaluated as the RCB, was highly prognostic for MFS. RCB could be used to guide NAT and post-NAT adjuvant trials in HRLPC.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"11 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143258067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal 追踪从原发性到转移性ccRCC的非基因进化:TRACERx肾
IF 23.4 1区 医学
European urology Pub Date : 2025-02-06 DOI: 10.1016/j.eururo.2025.01.019
Hanzhong Zhang, Ying Liu, Peng Luo, Linhui Wang, Aimin Jiang
{"title":"Re: Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal","authors":"Hanzhong Zhang, Ying Liu, Peng Luo, Linhui Wang, Aimin Jiang","doi":"10.1016/j.eururo.2025.01.019","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.01.019","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"55 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143192030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Immunogenomic Determinants of Exceptional Response to Immune Checkpoint Inhibition in Renal Cell Carcinoma 肾细胞癌对免疫检查点抑制异常反应的免疫基因组决定因素
IF 23.4 1区 医学
European urology Pub Date : 2025-02-06 DOI: 10.1016/j.eururo.2025.01.021
Hanzhong Zhang, Ying Liu, Anqi Lin, Linhui Wang, Aimin Jiang
{"title":"Re: Immunogenomic Determinants of Exceptional Response to Immune Checkpoint Inhibition in Renal Cell Carcinoma","authors":"Hanzhong Zhang, Ying Liu, Anqi Lin, Linhui Wang, Aimin Jiang","doi":"10.1016/j.eururo.2025.01.021","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.01.021","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"9 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143192029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to Jason Koehler and Abhinav Sidana’s Letter to the Editor re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025;87:526–533 回复Jason Koehler和Abhinav Sidana给编辑的信re: Guillaume Ploussard, Patrick colby, Thierry Chevallier等。全腺体或次全高强度聚焦超声与根治性前列腺切除术:前瞻性、非劣效性、非随机的HIFI试验。Urol欧元。在出版社。https://doi.org/10.1016/j.eururo.2024.11.006
IF 25.3 1区 医学
European urology Pub Date : 2025-02-06 DOI: 10.1016/j.eururo.2025.01.022
Pascal Rischmann , Bob-Valéry Occéan , Guillaume Ploussard
{"title":"Reply to Jason Koehler and Abhinav Sidana’s Letter to the Editor re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025;87:526–533","authors":"Pascal Rischmann ,&nbsp;Bob-Valéry Occéan ,&nbsp;Guillaume Ploussard","doi":"10.1016/j.eururo.2025.01.022","DOIUrl":"10.1016/j.eururo.2025.01.022","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 5","pages":"Pages e90-e91"},"PeriodicalIF":25.3,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143192028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life 膀胱癌患者的心理资源和恢复力特征:与虚弱和生活质量的关系
IF 23.4 1区 医学
European urology Pub Date : 2025-02-03 DOI: 10.1016/j.eururo.2025.01.011
Rodolfo Hurle, Bruno Bernardini, Roberto Contieri, Massimo Lazzeri
{"title":"Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life","authors":"Rodolfo Hurle, Bruno Bernardini, Roberto Contieri, Massimo Lazzeri","doi":"10.1016/j.eururo.2025.01.011","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.01.011","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"28 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143083766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信